Cardiovascular Revascularization Medicine最新文献

{"title":"Randomized comparison of sheath size for coronary intervention: time to hemostasis and risk of radial artery occlusion.","authors":"Christel G Aagren Nielsen, Martin B Rasmussen, Pernille T Rohde, Rebekka Vibjerg Jensen, Lars Jakobsen, Nicolaj Brejnholt Støttrup, Karsten T Veien, Ellen N Larsen, Mette G Charlot, Christian J Terkelsen","doi":"10.1016/j.carrev.2025.04.042","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.04.042","url":null,"abstract":"<p><strong>Background: </strong>Transradial access is the preferred approach for coronary procedures due to lower complication rates compared to femoral access. However, minimizing equipment for radial access may further reduce bleeding and radial artery occlusion (RAO).</p><p><strong>Aims: </strong>This study assessed whether the use of 5F sheaths, compared to 6F sheaths, reduces time to hemostasis and the risk of RAO in patients undergoing diagnostic coronary angiography and/or coronary intervention.</p><p><strong>Methods: </strong>3600 patients were randomized to 5F or 6F sheaths, except when operators preferred 6F sheaths. TR-band deflation and removal times were recorded, and radial artery patency was assessed at discharge using the reverse Barbeau test, with Types C and D indicating RAO.</p><p><strong>Results: </strong>942 patients were randomized to 5F and 945 to 6F sheath. In 1713 patients, 6F sheaths were chosen up front by the operator. In intention-to-treat analysis no significant differences were observed between the randomized groups in time to TR-band removal (101 vs. 105 min, p = 0.07), or RAO (1.6 % vs. 2.1 %, p = 0.44). A significant crossover to 6F sheaths occurred in the 5F group. In as-treated analyses, TR-band removal times were shorter with 5F compared to 6F and operator-preferred 6F sheaths (98.5 min, 105 min, 111 min, P < 0.01). No significant differences in RAO risk were observed between groups (1.8 %, 1.9 %, 1.2 %, P = 0.34).</p><p><strong>Conclusions: </strong>Although 5F sheaths reduced time to TR-band deflation and removal compared to 6F sheaths, no significant reduction in RAO was observed. High crossover rates suggest operator preference remains a key factor in sheath selection.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of covered stent grafts in the treatment of emergent access related complications","authors":"Michael Wilderman ,&nbsp;Kazuya Tateishi ,&nbsp;David O'Connor ,&nbsp;Sophia Simonian ,&nbsp;Anjali Ratnathicam ,&nbsp;Kristen Cook ,&nbsp;Lucius De Gregorio ,&nbsp;Hosam Hmoud ,&nbsp;Joseph De Gregorio","doi":"10.1016/j.carrev.2024.08.011","DOIUrl":"10.1016/j.carrev.2024.08.011","url":null,"abstract":"<div><h3>Background</h3><div>Large bore percutaneous access is becoming increasingly common. Parallel to this, we observe an increase in vascular access site complications such as bleeding, dissection, thrombosis or pseudo-aneurysms. This study was aimed to evaluate safety and efficacy of covered stent grafts for fixing large bore vascular access injuries.</div></div><div><h3>Methods</h3><div>A total of 147 Viabahn or Viabahn VBX (WL Gore) stent grafts which were placed across the inguinal ligament in emergent settings in 136 patients, were retrospectively analyzed. The two endpoints were the technical success rate, defined by complete arterial repair, and long-term stent graft patency. We also looked at the need for open conversion, wound infections, and in hospital and 30-day mortality. We followed the patients using duplex ultrasound and computed tomography angiogram to assess for arterial patency, freedom from intervention, stent kinking and clinical symptoms.</div></div><div><h3>Results</h3><div>30 Viabahn and 117 Viabahn VBX (WL Gore) stent grafts were placed in the distal external iliac artery and into the proximal common femoral artery of 136 patients. Indications for intervention were bleeding in 92 patients (68 %), flow limiting dissection in 41 patients (30 %) and symptomatic AVF in 3 patients (2 %). Primary technical success rate was 100 %. Limited 3-year follow up (101/136 patients) showed 99 % patency with no evidence of stent fracture, stenosis or kinking except in one patient who needed target lesion revascularization due to neointimal hyperplasia.</div></div><div><h3>Conclusions</h3><div>Covered stent grafts can be placed safely, efficiently, and effectively in the distal external iliac and common femoral arteries across the inguinal ligament. These stent grafts can be used as an alternative therapeutic option to open surgery in patients with large bore vascular access injuries.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"74 ","pages":"Pages 34-39"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial functional mitral regurgitation: Is a scoring system enough to evaluate residual regurgitation following transcatheter edge-to-edge repair?","authors":"Argyro Kalompatsou,&nbsp;Eirini Beneki,&nbsp;Markos Koukos,&nbsp;Kyriakos Dimitriadis,&nbsp;Konstantinos Tsioufis,&nbsp;Constantina Aggeli","doi":"10.1016/j.carrev.2024.12.002","DOIUrl":"10.1016/j.carrev.2024.12.002","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"74 ","pages":"Page 80"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-arterial nicardipine versus verapamil during transradial access coronary catheterization","authors":"Keshav Patel ,&nbsp;Melissa Duckett ,&nbsp;Mladen I. Vidovich ,&nbsp;Khalil Ibrahim","doi":"10.1016/j.carrev.2024.08.008","DOIUrl":"10.1016/j.carrev.2024.08.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Intra-arterial (IA) vasodilators are recommended during transradial access (TRA) to prevent radial artery spasm (RAS). The American Heart Association (AHA) recommends either IA verapamil, diltiazem, nicardipine, or nitroglycerin to prevent RAS. To our knowledge, the efficacy of RAS prevention and patient tolerability of verapamil and nicardipine has not been directly compared in a randomized fashion.</div></div><div><h3>Methods</h3><div>We conducted a prospective, single-blinded randomized clinical trial comparing the discomfort experienced by patients receiving either 400 μg of IA nicardipine (<em>n</em> = 26) or 5 mg of IA verapamil (<em>n</em> = 29). Patient discomfort and/or pain was assessed using the Visual Analogue Scale (VAS) both before and after IA administration of nicardipine or verapamil.</div></div><div><h3>Results</h3><div>There was a statistically significant difference in mean change in VAS scores between the 2 groups, with an average increase in VAS score of 0.88 in the nicardipine group and 4.81 in the verapamil group (<em>p</em> &lt; 0.0001). The overall rate of RAS was low in our study (5.5 %) with no significant difference in RAS incidence between the 2 groups (<em>p</em> = 0.465). The nicardipine group had 2 RAS cases (7.7 %), with 1 requiring a change in strategy (3.8 %). The verapamil group had 1 RAS case (3.4 %) that did not require a change in strategy.</div></div><div><h3>Conclusion</h3><div>In this trial, we showed that nicardipine causes significantly less discomfort and pain compared to verapamil during IA administration for TRA cardiac catheterization.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"74 ","pages":"Pages 40-44"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes following TAVR in patients with cardiogenic shock: A systematic review and meta-analysis","authors":"Ahmad Jabri ,&nbsp;Mohammed Ayyad ,&nbsp;Maram Albandak ,&nbsp;Ahmad Al-Abdouh ,&nbsp;Luai Madanat ,&nbsp;Basma Badrawy Khalefa ,&nbsp;Laith Alhuneafat ,&nbsp;Asem Ayyad ,&nbsp;Alejandro Lemor ,&nbsp;Mohammed Mhanna ,&nbsp;Zaid Al Jebaje ,&nbsp;Raef Fadel ,&nbsp;Pedro Engel Gonzalez ,&nbsp;Brian O'Neill ,&nbsp;Rodrigo Bagur ,&nbsp;Ivan D. Hanson ,&nbsp;Amr E. Abbas ,&nbsp;Tiberio Frisoli ,&nbsp;James Lee ,&nbsp;Dee Dee Wang ,&nbsp;Pedro Villablanca","doi":"10.1016/j.carrev.2024.08.002","DOIUrl":"10.1016/j.carrev.2024.08.002","url":null,"abstract":"<div><h3>Background</h3><div>While transcatheter aortic valve replacement (TAVR) has broadened treatment options for critically ill patients, outcomes among those with concomitant cardiogenic shock (CS) are not well-explored.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive search of major databases for studies comparing outcomes following TAVR in patients with and without CS since inception up to October 31, 2023. Our meta-analysis included five non-randomized observational. Dichotomous outcomes were assessed using the Mantel-Haenszel method (risk ratio, 95 % CI), and continuous outcomes were evaluated using mean difference and 95 % CI with the inverse variance method. Statistical heterogeneity was determined using the inconsistency test (I²).</div></div><div><h3>Results</h3><div>Among 26,283 patients across five studies, 30-day mortality was higher in the CS group (7267 patients; 27.6 %) compared to those without CS (OR 3.41, 95 % CI [2.01, 5.76], <em>p</em> &lt; 0.01), as well as 30-day major vascular complications (OR 1.72, 95 % CI [1.54, 1.92], p &lt; 0.01). At 1-year follow-up, there was no statistically significant difference in mortality rates between the compared groups (OR 2.68, 95 % CI [0.53, 13.46], <em>p</em> = 0.12). No significant between-group differences were observed in the likelihood of 30-day aortic valve reintervention (OR 3.20, 95 % CI [0.63, 16.22], <em>p</em> = 0.09) or post-TAVR aortic insufficiency (OR 0.91, 95 % CI [0.33, 2.51], <em>p</em> = 0.73). Furthermore, 30-day stroke, pacemaker implantation, and in-hospital major bleeding were comparable between both cohorts.</div></div><div><h3>Conclusion</h3><div>Among patients undergoing TAVR, short-term mortality is higher but one-year outcomes are similar when comparing those with, to those without, CS. Future studies should examine whether TAVR outcomes are improved when the procedure is delayed to optimize CS and when delay is not possible, whether particular management strategies lead to more favorable periprocedural outcomes.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"74 ","pages":"Pages 8-13"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous renal denervation in the management of kidney-related pain syndromes: a case series.","authors":"K A Saville, V J M Zeijen, R Zietse, M Salih, D A Hesselink, J Daemen","doi":"10.1016/j.carrev.2025.04.041","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.04.041","url":null,"abstract":"<p><strong>Introduction: </strong>Positive effects on pain reduction following renal denervation (RDN) have been described in patients with kidney-related pain syndromes, yet data on the safety and efficacy of redo RDN procedures are limited.</p><p><strong>Methods: </strong>Consecutive patients with a history of chronic loin pain, hypertension and preserved renal function (eGFR ≥40 ml/min) scheduled for RDN were included. Changes in perceived pain, opioid and antihypertensive medication use, and blood pressure were prospectively assessed 3 months after each procedure.</p><p><strong>Results: </strong>Two patients presented with a history of Autosomal Dominant Polycystic Kidney Disease (n = 2) and one with Loin Pain Hematuria Syndrome (n = 1). Two patients underwent a redo RDN. After the initial procedures, a reduction in perceived pain, along with a 50 % and 75 % reduction in the daily dosage of opioids, was observed in two patients. One patient showed no reduction in perceived pain or opioid use and underwent a redo procedure after 3 years, again with no reduction in perceived pain or opioid use. One patient who initially responded returned at 2 years with recurrent symptoms and underwent a redo procedure. After 3 months, a significant improvement in pain and opioid use was observed. Mean 24-hour systolic blood pressure decreased in all patients and after each procedure with a mean decrease of 12 mmHg. No adverse events were observed.</p><p><strong>Conclusion: </strong>In hypertensive patients with kidney-related pain syndromes, percutaneous RDN may be considered as an alternative treatment option to reduce pain severity and improve blood pressure control. Redo procedures may be considered in patients with recurrent symptoms after an initial response.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project","authors":"Enrico Poletti ,&nbsp;Ignacio Amat-Santos ,&nbsp;Enrico Criscione ,&nbsp;Antonio Popolo Rubbio ,&nbsp;Mario García-Gómez ,&nbsp;Mateusz Orzalkiewicz ,&nbsp;Manuel Pan ,&nbsp;Antonio Sisinni ,&nbsp;Mattia Squillace ,&nbsp;Bruno García del Blanco ,&nbsp;Francesco Bruno ,&nbsp;Vasileios Panoulas ,&nbsp;Radoslaw Pracon ,&nbsp;Ole De Backer ,&nbsp;Maurizio Taramasso ,&nbsp;Giuliano Costa ,&nbsp;Marco Barbanti ,&nbsp;Nicolas M. Van Mieghem ,&nbsp;Damiano Regazzoli ,&nbsp;Antonio Mangieri ,&nbsp;Luca Testa","doi":"10.1016/j.carrev.2024.08.007","DOIUrl":"10.1016/j.carrev.2024.08.007","url":null,"abstract":"<div><h3>Background</h3><div>The off-label utilization of transcatheter heart valve (THV) devices for the treatment of inoperable or high-surgical risk patients with pure native aortic valve regurgitation (NAVR) has demonstrated suboptimal outcomes, both with self- and balloon-expandable (BE) devices. The aim of this study is to compare the use of different BE scaffolds in treating pure NAVR.</div></div><div><h3>Methods</h3><div>Consecutive patients with pure severe NAVR who were deemed to be at high-risk and were treated with last-generation BE-THVs among seventeen Centers in Europe and US. Technical and device success rates were the primary objectives.</div></div><div><h3>Results</h3><div>Between February 2018 and July 2023, among 144 patients, 41 (28 %) received a MyVal device and 103 (72 %) were treated with a Sapien THV. Patients treated with a MyVal THV had an extra-large annulus more frequently compared to the Sapien group (49%vs.20 %, <em>p</em> &lt; 0.001).</div><div>Technical and device success rates were 90 % and 81 %, respectively, <em>p</em> &gt; 0.1. The rate of THV migration/embolization (MyVal 4.9%vs. Sapien 11 %, <em>p</em> = 0.4) and second valve needed (4.9%vs.7.8 %, <em>p</em> = 0.7) were numerically lower in the MyVal group, whereas the rate of at least moderate paravalvular leak (15%vs.7.8 %, <em>p</em> = 0.2) and permanent pacemaker implantation (25%vs.18 %, <em>p</em> = 0.16) were numerically higher in the Myval group.</div></div><div><h3>Conclusions</h3><div>Off-label use of BE devices for pure NAVR represents a potential alternative in high-risk patients in the absence of dedicated devices. However, BE in NAVR is associated with suboptimal outcomes. The availability of larger THV sizes may introduce transcatheter aortic valve replacement as an effective treatment for patients traditionally deemed unsuitable.</div></div><div><h3>Non-standard abbreviations and acronyms</h3><div>AR = aortic regurgitation, BE = balloon-expandable, NAVR = native aortic valve regurgitation, PM = pacemaker, TAVR = transcatheter aortic valve replacement, THV = transcatheter heart valve, TVEM = transcatheter valve embolization and migration, VARC-3 = Valve Academic Research Consortium 3.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"74 ","pages":"Pages 28-33"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142093978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stress testing before PCI","authors":"Spencer B. King III","doi":"10.1016/j.carrev.2025.04.029","DOIUrl":"10.1016/j.carrev.2025.04.029","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"74 ","pages":"Page 85"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Comparison of FFRangio sizing tool and IVUS measurements - So how does it measure up?","authors":"Krystyna Bronchard, Edward Ha, Yuhei Kobayashi","doi":"10.1016/j.carrev.2025.04.037","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.04.037","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care consultation in patients hospitalized with out-of-hospital cardiac arrest: Impact on invasive procedures, do-not-resuscitate orders, and healthcare costs","authors":"Abdilahi Mohamoud ,&nbsp;Nadhem Abdallah ,&nbsp;Abdirahman Wardhere ,&nbsp;Mahmoud Ismayl","doi":"10.1016/j.carrev.2024.08.003","DOIUrl":"10.1016/j.carrev.2024.08.003","url":null,"abstract":"<div><h3>Background</h3><div>The impact of palliative care consultation on the management and outcomes of patients hospitalized with out-of-hospital cardiac arrest (OHCA) remains poorly understood. This study examined associations between palliative care consultation and in-hospital outcomes of patients hospitalized with OHCA, stratified by survival status.</div></div><div><h3>Method</h3><div>This cross-sectional study used data from the National Inpatient Sample (2016–2021). Adult patients hospitalized with OHCA who received cardiopulmonary resuscitation were included. Multivariable analyses assessed associations between palliative care consultation and outcomes in non-terminal and terminal OHCA hospitalizations, adjusting for demographics, hospital characteristics, and comorbidities.</div></div><div><h3>Results</h3><div>Among 488,700 OHCA hospitalizations, palliative care consultation was associated with lower odds of invasive procedures in non-terminal hospitalizations, including percutaneous coronary intervention (PCI) (aOR 0.30, 95 % CI 0.25–0.36), mechanical circulatory support (aOR 0.54, 95 % CI 0.44–0.68), permanent pacemaker (aOR 0.27, 95 % CI 0.20–0.37), implantable cardioverter defibrillator insertion (aOR 0.22, 95 % CI 0.16–0.31), and cardioversion (aOR 0.62, 95 % CI 0.55–0.70). In terminal hospitalizations, palliative care was associated with lower odds of PCI (aOR 0.78, 95 % CI 0.70–0.87) and cardioversion (aOR 0.91, 95 % CI 0.85–0.97), but higher odds of therapeutic hypothermia (aOR 3.12, 95 % CI 2.72–3.59), gastrostomy (aOR 1.22, 95 % CI 1.05–1.41), and renal replacement therapy (aOR 1.19, 95 % CI 1.12–1.26). Palliative care was associated with higher DNR utilization in both subgroups and lower hospital costs in non-terminal hospitalizations but higher costs in terminal hospitalizations.</div></div><div><h3>Conclusion</h3><div>Palliative care consultation in OHCA is associated with differences in invasive procedures, DNR utilization, and hospital costs, varying by survival status.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"74 ","pages":"Pages 64-70"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}